Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Articles|July 18, 2012
- Psychiatric Times Vol 29 No 7
- Volume 29
- Issue 7
The Page Turner
Author(s)Richard M. Berlin, MD
And while the spotlight admires . . . the soloist’s passion, I love . . . the page turner even more,
Advertisement
stands heron-still, flexed,
fully alert, focused on the music,
her hand a burst of wind
tossing a white sheet.
And while the spotlight admires
the soloist’s passion, I love
the page turner even more,
remembering the thrill
of starting at the bottom-
tracking labs, holding retractors,
the lowest rung a badge of honor,
all the confidence earned when
we learn to accept our place.
Articles in this issue
over 14 years ago
Narcissistic Personality Disorder: Rethinking What We Knowover 14 years ago
A “Real” Psychiatristover 14 years ago
FDA Panel Votes to Curtail Cranial Electrotherapy Stimulatorsover 14 years ago
Dr Nada Stotland Joins Our Editorial Boardover 14 years ago
Sex Orientation Change Therapy: Back in the Headlinesover 14 years ago
The Correlation Between Sleep-Disordered Breathing and Psychiatryover 14 years ago
The Role of Melatonin in the Circadian Rhythm Sleep-Wake CycleAdvertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5